Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Psoriasis
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Psoriasis
    Psoriasis Associated With Cardiovascular Disease, Increased Mortality - (DGNews)
    Chondroitin Sulphate Effective in Patients With Concomitant Knee Osteoarthritis and Psoriasis: Presented at EULAR - (DGDispatch)
    Golimubab Shows Long-Term Efficacy in Treatment of Psoriatic Arthritis: Presented at EULAR - (DGDispatch)
    Nationwide Recall of Remaining Batches of Efalizumab Initiated in Europe - (DGDispatch)
    Home versus outpatient ultraviolet B phototherapy for mild to severe psoriasis: pragmatic multicentre randomised controlled non-inferiority trial (PLUTO study) - (BMJ)

    News archive

     Recent webcasts/CME - Psoriasis
    • Using Biologics to Improve Both Physical and Social Function in Rheumatic Diseases
    • Rheumatic Diseases: Using Anti-TNF-alpha Agents to Improve Everyday Patient Function
    • Treating to Target: Long-Term Safety and Efficacy in Rheumatoid Arthritis
    • Moderate-to-Severe Psoriasis and Psoriatic Arthritis: Reducing the Clinical and Economic Burden Through Effective Treatment Protocols
      Treatment Options for Moderate to Severe Plaque Psoriasis

      Webcasts/CME archive

       Recent cases - Psoriasis
        Concomitant Xeroderma Pigmentosum and Disseminated Small Plaque Psoriasis - The First Case of an Antinomic Association: A Case Report
        Extensive Psoriasis Induced by Pegylated Interferon: A Case Report
        Pulmonary Sarcoidosis Associated with Psoriasis Vulgaris: Coincidental Occurrence or Causal Association? Case Report
        Leukemia Cutis Resembling a Flare-Up of Psoriasis
        Pimecrolimus 1 Percent Cream in the Treatment of Psoriasis in a Child

        Cases archive
          




        my personal edition > psoriasis > news
        divider

          E-Mail this DGDispatch to a colleague

        DGDispatch


        Tazarotene Gel Improves Fingernail Psoriasis: Presented at WCD

        By Jill Stein
        Special to DG News

        PARIS, FRANCE -- July 2, 2002 -- Evening application of tazarotene 0.1 percent gel to psoriatic fingernails can produce an impressive clinical improvement.

        Dr. Richard K. Scher and colleagues at Columbia-Presbyterian Medical Center in New York, New York, presented the results today at the 20th World Congress of Dermatology (WCD). Their study enrolled 31 patients with psoriasis affecting at least two fingernails.

        Patients were randomised to either tazarotene 0.1 percent gel or vehicle gel. They applied the gel to each target fingernail and the surrounding nail folds every evening for up to 24 weeks. One target fingernail was occluded with polyethylene film during the treatment period. No other medications were allowed on the fingernails.

        All patients were adults with psoriasis that was characterized by at least three of the following: pitting, onycholysis, subungual hyperkeratosis, leukonychia, nail plate crumbling and/or loss, splinter hemorrhages, and nail bed discoloration.

        Patients were ineligible if they had psoriasis for less than six months or if either of their two target fingernails (designated by the investigator) had a positive potassium hydroxide (KOH) or dermatophyte/fungal culture.

        Results showed that tazarotene was consistently more effective than the vehicle gel in reducing onycholysis in occluded nails and nonoccluded nails. Tazarotene was also significantly more effective in reducing pitting in occluded nails. There were no other significant differences between the two groups.

        Five patients (all in the tazarotene group) reported treatment-related adverse events, which included peeling and erythema of proximal nail fold skin, skin irritation, periungual irritation, and paronychia. All such adverse events were mild or moderate.

        The study was sponsored by Allergan Skin Care of Irvine, California.



        E-Mail this DGDispatch to a colleague   To print, use this version






        All contents Copyright (c) 1995-2009 Doctor's Guide Publishing Limited. All rights reserved.



        The NTK initiative. Physicians helping physicians identify Need-To-Know science
           Feedback
        Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
        Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
        1
        2
        3
        4
        5
        6
        7
        Send